What Ketamine Is, and What It Is Not
Ketamine is a medication with a long history in anesthesia. In mental health care, it has drawn attention because some people with depression experience a meaningful shift in symptoms sooner than they have with conventional medication alone. That possibility matters, especially when depression has become heavy, repetitive, or resistant to prior care.
At the same time, ketamine is not a simple answer to a complicated illness. Psychiatric use of ketamine, including ketamine for depression, is off-label. That means it is not FDA-approved specifically as a depression treatment, even though clinicians may prescribe it when clinical judgment, screening, and informed consent support its use.
Our work with ketamine therapy begins with that level of honesty. We do not frame a treatment experience as a cure, and we do not assume that one person’s response will predict yours. Depression can have biological, psychological, social, and medical dimensions. A treatment plan has to make room for all of them.
Why Rapid Symptom Change Has Drawn Attention
For many people, standard antidepressants can take weeks before their full effects are clear. Ketamine has been studied differently because its effects, when they occur, may emerge on a shorter timeline. In a placebo-controlled trial of intravenous ketamine used alongside ongoing treatment for treatment-resistant depression, improvement was assessed as early as the first day after dosing (Fava et al., 2020).
That does not mean everyone feels better immediately. It does not mean the first shift will last. It means the timeline can be different.
Research into depression increasingly includes the glutamate system, which is involved in communication between nerve cells. Ketamine affects this system in ways that appear distinct from many traditional antidepressants. A review of glutamate and GABA signaling in depression describes why these pathways have become important targets for newer treatments (Duman et al., 2019).
The science is still developing. The lived experience is also varied. Some patients describe a decrease in the relentless pressure of depressive thinking. Others notice subtle changes first, such as greater emotional distance from hopeless thoughts or more capacity to complete ordinary tasks. Others do not experience a meaningful benefit. We make room for each possibility.
What the Evidence Can, and Cannot, Tell You
The research base for ketamine in depression is substantial enough to warrant serious clinical attention, particularly for treatment-resistant depression. At the same time, it is not a promise about an individual outcome.
A broad review of new and emerging treatments for major depression identifies ketamine and related approaches as important developments, while also placing them within a larger landscape of treatment options (Marwaha et al., 2023). That context matters. Ketamine may be one part of care, rather than the entire plan.
Research also has limits that are easy to overlook when people are searching for relief:
Studies may involve different doses, routes of administration, treatment schedules, and patient populations.
“Response” in a study has a specific definition, but it may not capture every part of daily life that matters to you.
Short-term symptom change and sustained wellness are not the same question.
Participants in clinical trials are carefully screened, monitored, and followed, which may not mirror every real-world circumstance.
One systematic review and meta-analysis comparing ketamine with electroconvulsive therapy found that, among selected patients with nonpsychotic, treatment-resistant major depressive episodes, ketamine may be an alternative to ECT (Rhee et al., 2022). That finding does not apply to every major depressive episode, including psychotic presentations, and it is not a ranking for every patient. Treatment choices depend on symptom severity, history, preferences, risks, and practical circumstances.
How We Think About Individual Response
Depression is not one uniform condition. Two people may use the same word for what they are experiencing, while living with profoundly different patterns of sleep, anxiety, trauma, medical illness, medication history, substance use, or loss.
That is why we start with a careful conversation. We want to understand what depression has looked like for you, what you have tried, what has helped even a little, and what has made things harder. Our ketamine for depression care is built around clinical screening and individualized planning, not around a one-size-fits-all promise.
Individual response can vary for many reasons, including:
the duration and severity of depressive symptoms
previous medication and therapy history
co-occurring mental or physical health concerns
sleep, stress, support systems, and substance use
the degree to which follow-up care fits into everyday life
We also consider whether medication management should be part of the larger picture. Medication decisions should not be made in isolation, particularly when someone is already taking psychiatric medications or managing other health conditions.
Safety, Monitoring, and the Questions Worth Asking
Ketamine deserves respect. It can cause temporary dissociation, changes in perception, nausea, dizziness, sedation, or increases in blood pressure. These effects are part of why appropriate screening and monitoring matter.
There are also important unanswered questions about long-term use, optimal dosing, and risks associated with repeated exposure. A recent review of potential neurotoxic effects and safety questions emphasizes the need to weigh potential benefits against known and emerging risks (Li et al., 2025). We take that balance seriously.
During a consultation, we encourage you to ask direct questions:
What form of ketamine is being considered, and why?
What does monitoring look like before, during, and after treatment?
How will we assess whether treatment is helping?
What happens if symptoms return or do not change?
How might therapy, daily routines, or other clinical supports fit alongside treatment?
For some people, structured emotional work is an important part of longer-term care. Our psychotherapy and coaching services can help patients think through patterns, relationships, habits, and the practical work of carrying change into ordinary life. The medicine may create an opening for some patients. What comes after that opening still matters.
A Note About Esketamine and Other Options
Ketamine and esketamine are related, but they are not interchangeable terms. SPRAVATO® is an FDA-approved esketamine nasal spray with specific prescribing and monitoring requirements. Research on esketamine used with an oral antidepressant for relapse prevention found a lower risk of relapse among certain patients who continued treatment after achieving stable response or remission (Daly et al., 2019).
The existence of several treatment options does not mean every option is right for every person. A meaningful consultation considers the whole clinical picture, including safety, access, treatment history, and your goals.
Frequently Asked Questions
How quickly can ketamine affect depression symptoms?
Some people report changes soon after treatment, while others notice no immediate shift or need more time to understand whether there is a benefit. Research supports the possibility of rapid symptom change for some patients, but there is no reliable personal timetable.
Is ketamine only considered after other treatments have failed?
Treatment history is important, particularly when depression has not improved with prior approaches. Still, the right next step depends on a careful clinical assessment rather than a single rule.
Will I need other support alongside ketamine?
Many patients benefit from a broader plan that may include therapy, medication review, supportive relationships, sleep and routine changes, or other forms of care. We discuss this in the context of your needs rather than treating ketamine as separate from the rest of your life.
What will treatment cost?
We believe cost should be understood before you make a decision. You can review pricing and treatment options, and we can discuss practical questions during your consultation.
Key Takeaways
Ketamine has become an important area of depression research because some patients experience symptom change on a faster timeline than they have with other approaches. The evidence is encouraging, but it is not universal, and it does not remove the need for careful screening, monitoring, and follow-up.
At Valor Health Solutions, we emphasize clear expectations, individualized care, and a treatment plan that respects the complexity of depression. If you are considering ketamine for depression in Johnson City, TN, we invite you to contact our team at 888-214-2144 to begin the conversation.
When Depression Feels Unsafe
Ketamine treatment is not emergency care. If you are in immediate danger, call 911 or go to the nearest emergency department. If you are having thoughts of suicide, call or text 988 for the 988 Suicide and Crisis Lifeline (988 Suicide and Crisis Lifeline, n.d.).
Medical Disclaimer
This article is for general educational purposes and is not medical advice. A qualified clinician should evaluate your individual history, medications, symptoms, and safety considerations before any treatment decision is made.
Works Cited
1. Fava M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). https://pubmed.ncbi.nlm.nih.gov/30283029/
2. Duman RS, et al. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. https://pubmed.ncbi.nlm.nih.gov/30946828/
3. Marwaha S, et al. Novel and emerging treatments for major depression. https://pubmed.ncbi.nlm.nih.gov/36535295/
4. Rhee TG, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. https://pubmed.ncbi.nlm.nih.gov/36260324/
5. Li SW, et al. Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies. https://pubmed.ncbi.nlm.nih.gov/40926573/
6. Daly EJ, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/31166571/
7. 988 Suicide and Crisis Lifeline. https://988lifeline.org/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.
